neutral
Recently
Motilal Oswal reiterates buy call on Sun Pharma
Motilal Oswal reiterated a buy call on Sun Pharma with a target of ₹1,940 citing strong specialty portfolio growth and improving earnings visibility.
Motilal Oswal has maintained a buy rating on Sun Pharma with a target price of ₹1,940. The brokerage cited strong specialty portfolio performance steady India formulations growth and improving margins. Analysts highlighted Sun Pharma’s leadership in dermatology and chronic therapies alongside controlled costs. They expect earnings visibility to improve supported by new launches stable US business and sustained cash flow generation ahead.